These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8456474)

  • 21. Tolerance of rat liver allografts induced by short-term selective immunosuppression combining monoclonal antibodies directed against CD25 and CD54 with subtherapeutic cyclosporine.
    Gassel HJ; Otto C; Gassel AM; Meyer D; Steger U; Timmermann W; Ulrichs K; Thiede A
    Transplantation; 2000 Mar; 69(6):1058-67. PubMed ID: 10762208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody. II. Results after a second kidney transplantation.
    Hourmant M; Le Mauff B; Cantarovich D; Dantal J; Baatard R; Denis M; Jacques Y; Karam G; Soulillou JP
    Transplantation; 1994 Jan; 57(2):204-7. PubMed ID: 8310508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation.
    van Gelder T; Balk AH; Jonkman FA; Zietse R; Zondervan P; Hesse CJ; Vaessen LM; Mochtar B; Weimar W
    Transplantation; 1996 Jul; 62(1):51-5. PubMed ID: 8693545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.
    Rosen HR; Shackleton CR; Higa L; Gralnek IM; Farmer DA; McDiarmid SV; Holt C; Lewin KJ; Busuttil RW; Martin P
    Am J Gastroenterol; 1997 Sep; 92(9):1453-7. PubMed ID: 9317061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic rejection after orthotopic liver transplantation is increased under induction therapy with interleukin-2 receptor antibody BT563.
    Langrehr JM; Lohmann R; Raakow R; Jonas S; Klupp J; Bechstein WO; Neuhaus R; Neuhaus P
    Transplant Proc; 2001 May; 33(3):2290-1. PubMed ID: 11377531
    [No Abstract]   [Full Text] [Related]  

  • 26. The long-term outcome of OKT3 compared with cyclosporine prophylaxis after liver transplantation.
    McDiarmid SV; Busuttil RW; Levy P; Millis MJ; Terasaki PI; Ament ME
    Transplantation; 1991 Jul; 52(1):91-7. PubMed ID: 1858160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3.
    Renlund DG; O'Connell JB; Gilbert EM; Hammond ME; Burton NA; Jones KW; Karwande SV; Doty DB; Menlove RL; Herrick CM
    Transplantation; 1989 Apr; 47(4):599-605. PubMed ID: 2523099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
    Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of antilymphocyte induction therapy in liver transplantation.
    Wall WJ
    Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S64-70. PubMed ID: 10431019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized trial of OKT3-based versus cyclosporine-based immunoprophylaxis after liver transplantation. Long-term results of a European and Australian multicenter study.
    Farges O; Ericzon BG; Bresson-Hadni S; Lynch SV; Höckerstedt K; Houssin D; Galmarini D; Faure JL; Baldauf C; Bismuth H
    Transplantation; 1994 Oct; 58(8):891-8. PubMed ID: 7940732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody. I. Results after combined pancreas and kidney transplantation.
    Cantarovich D; Le Mauff B; Hourmant M; Dantal J; Baatard R; Denis M; Jacques Y; Karam G; Paineau J; Soulillou JP
    Transplantation; 1994 Jan; 57(2):198-203. PubMed ID: 8310507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
    Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
    Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
    Nashan B; Light S; Hardie IR; Lin A; Johnson JR
    Transplantation; 1999 Jan; 67(1):110-5. PubMed ID: 9921806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment with Lo-Tact-1, a monoclonal antibody to the interleukin-2 receptor, in kidney transplantation].
    Hiesse C; Lantz O; Kriaa F; Noury J; Fries D; Charpentier B; Bazin H
    Presse Med; 1991 Nov; 20(40):2036-8. PubMed ID: 1837120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunosuppressive T-cell antibody induction for heart transplant recipients.
    Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3.
    Kirklin JK; Bourge RC; White-Williams C; Naftel DC; Thomas FT; Thomas JM; Phillips MG
    J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative trial of immunoprophylaxis with RATG versus OKT3.
    Griffith BP; Kormos RL; Armitage JM; Dummer JS; Hardesty RL
    J Heart Transplant; 1990; 9(3 Pt 2):301-5. PubMed ID: 2113093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial.
    Eason JD; Loss GE; Blazek J; Nair S; Mason AL
    Liver Transpl; 2001 Aug; 7(8):693-7. PubMed ID: 11510013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation. A plea for multicenter immunosuppressive trials.
    Ross DJ; Jordan SC; Nathan SD; Kass RM; Koerner SK
    Chest; 1996 Apr; 109(4):870-3. PubMed ID: 8635362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction therapy with cyclosporine without cytolytic agents results in a low incidence of acute rejection without significant renal impairment in heart transplant patients.
    Jazzar A; Fagiuoli S; Sisson S; Zuhdi N; Cooper DK
    Clin Transplant; 1995 Aug; 9(4):334-9. PubMed ID: 7579743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.